FY2025 · ended Dec 31, 2025 · Revenue $27.64M, +4.3% YoY · Filed Mar 30, 2026
ImmuCell Corporation (ICCC) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $27.6 million and a net loss of $1.0 million. Free cash flow was $1.2 million. As of Jun 30, 2026 it held $8.9 million in cash and investments and $12.4 million in total debt.
Revenue (TTM)
$30.68M
+8.5% vs year-ago TTM
Net income (TTM)
$787,373
-55.3% vs year-ago TTM
Operating cash flow (TTM)
$5.89M
+132.6% vs year-ago TTM
Free cash flow (TTM)
$4.21M
+138.9% vs year-ago TTM
EPS (TTM)
$0.09
-56.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
9.05M
+0.7% vs prior year
Net cash
$-3.59M
as of Jun 30, 2026
Operating margin
12.6%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- ICCC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Portland, ME
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 811641
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M | $19.2M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M | $257,385 |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M | -$78,292 |
| Diluted EPS | -$0.12 | -$0.26 | -$0.75 | -$0.32 | -$0.01 |
| Operating cash flow | $2.5M | $357,903 | -$4.7M | -$1.5M | $954,170 |
| Free cash flow | $1.2M | -$107,822 | -$6.6M | -$5.5M | -$1.7M |
| Total assets | $42.5M | $45.1M | $43.8M | $44.9M | $44.5M |
| Total liabilities | $15.5M | $17.6M | $18.8M | $14.5M | $11.9M |
| Stockholders' equity | $27.1M | $27.5M | $25.0M | $30.4M | $32.6M |
| Cash and investments | $3.8M | — | $978,741 | $5.8M | $10.2M |
| Total debt | $13.2M | $13.6M | $15.2M | $12.5M | $971,603 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 13, 2026 | Oct 12, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 9, 2026 | Jul 9, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 10, 2026 | Jun 4, 2026 |
All 795 ImmuCell Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.